source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushVivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.Fierce Biotech · 1d ago↗ source